Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/02/2021
Excerpt:
RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of...Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) (1.1)...Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
Secondary therapy:
Chemotherapy; CHOP
Source:
Title:
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Excerpt:
...- Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which...
Trial ID:
Source:
Title:
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
Excerpt:
...Phase I and Phase II: Confirmed diagnosis of mantle cell lymphoma with CD20 positivity in tissue biopsy....
Trial ID:
More C2 evidence
Source:
Title:
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Excerpt:
...- Biopsy confirmed, CD20 positive diffuse large B-cell lymphoma, primary mediastinal b-cell lymphoma, mantel cell lymphoma, transformed indolent lymphoma, high grade-B-cell lymphoma; AND bone marrow must show == 15% cellularity within 42 days of study registration...
Trial ID:
Source:
Title:
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL
Excerpt:
...- Pathologically confirmed CD20 positive diffuse large B-cell lymphoma (DLBCL) after surgical resection...
Trial ID:
Source:
Title:
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Excerpt:
...Histologically confirmed CD20 positive DLBCL 2....
Trial ID:
Source:
Title:
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphoma
Excerpt:
...For first randomization: - Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL) based upon a representative histology specimen according to the WHO classification (see appendix A) - DLBCL must be CD20 positive - Ann Arbor stages II-IV (see appendix C) - Age 18-65 years and age-adjusted IPI 1-3 OR age 66-80 years and age-adjusted IPI 0-3 - WHO performance status 0 – 2 (see appendix E) - Written informed consent For second randomization: Patients achieving a CR (or FDG-PET negative PR/CRu) after 6 (elderly) or 8 (young patients) cycles of R-CHOP14 will be randomized to maintenance treatment with rituximab or no further treatment. ...
Trial ID:
Source:
Title:
Prospective multicenter phase I-II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-Cell Lymphoma (DLBCL).
Excerpt:
...Histologic subtypes as follows: a. CD20 positive Diffuse large B-Cell lymphoma b. CD20 positive Follicular grade IIIb 2. ...
Trial ID:
Source:
Title:
PET-RIMCEB:Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patientsA phase III studyA randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas+A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas
Excerpt:
...• Age 18-60 years• Newly diagnosed, CD20 positive, untreated diffuse large B-cell lymphoma or composite follicular/diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma (according to the WHO classification) • High intermediate or high risk according to age adjusted International Prognostic Index (aaIPI 2-3) • No significant organ dysfunction, no active uncontrolled disease• ECOG Performance Status 0-3 • Ejection fraction of at least 50% as determined by echocardiography or alternative suitable method • Signed informed consent...
Trial ID:
Source:
Title:
Multicenter, randomized, double-blind, and parallel active controlled trial for comparing the efficacy and safety of Haizheng recombinant human - mouse chimeric anti-CD20 monoclonal antibody injection (HS006) combined with CHOP(Hi-chop) and Rituximab combined with CHOP(R-chop) in initial treatment for patients with diffuse large B
Excerpt:
...Histopathologically diagnosed with CD20 positive diffuse large B-cell lymphoma, non-specific type (DLBCL, NOS). ...
Trial ID:
Source:
Title:
A phase III, open-label, prospective, two-armed, multicenter, randomized,group sequential study to evaluate the efficacy and safety of subsequenttreatment with the Zevalin (ibritumomab tiuxetan) study regimen versusobservation in patients with diffuse large B-cell lymphoma who are incomplete remission after first-line CHOP-rituximab (CHOP-R) therapy
Excerpt:
...Central pathology review confirming the DLBCL diagnosis and CD20 positivity, and no evidence of DLBCL in bone marrow3. ...
Trial ID:
Source:
Title:
A preliminary clinical trial on the safety and efficacy of high-purity human NK cell (hpNK) injection combined with rituximab in the treatment of CD20-positive diffuse large B-cell lymphoma (CD20+ r/r DLBCL)
Excerpt:
...Histologically confirmed CD20-positive (CD20+) relapsed or refractory diffuse large B-cell lymphoma (DLBCL); 3. ...
Trial ID:
Source:
Title:
A multicenter, randomized, single blind, multi dose, positive drug parallel controlled phase II clinical trial to evaluate the efficacy and safety of Hisun recombinant chimeric human-mouse anti-CD20 monoclonal antibody injection combined with CHOP (Hi CHOP) regimen in previously untreated patients with diffuse large B-cell 
Excerpt:
...Previously untreated patients with a confirmed pathologic diagnosis of Diffuse large B cell-non-Hodgkin's lymphoma (DLBCL) and CD20 positive in immunohistochemical test. ...
Trial ID:
Source:
Title:
Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma, eligible for transplantation followed by randomised maintenance treatment with Rituximab
Excerpt:
...Patients with CD20 positive diffuse large B-cell lymphoma.Disease must be histologically proven in case ofrelapse or partial responseAged 18-65 Eligible for transplanatationECOG performance ...
Trial ID:
Source:
Title:
Ofatumumab for the treatment of lymphomalease
Excerpt:
...CD20 positive DLBCL or grade 3b follicular lymphoma (FL) at original diagnosis. ...
Trial ID:
Source:
Title:
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Excerpt:
...Lenalidomide naïve; relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) following at least one prior standard systemic treatment regimen including systemic chemo-, immune-; or chemo-immunotherapy and at least one prior line of salvage therapy with...
Trial ID:
Source:
Title:
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Excerpt:
...- Histologically confirmed cluster of differentiation antigen 20 (CD20) positive Diffuse Large B-Cell Lymphoma according to the World Health Organization/Revised European-American Classification of Lymphoid Neoplasms (WHO/REAL) classification - Age > or =18 years - Performance status < or = 2 on the Eastern Cooperative Oncology Group (ECOG) scale - Women of child-bearing potential must agree to use effective contraception for the entire treatment period and during the 12 months thereafter ...
Source:
Title:
Split-Dose R-CHOP for Older Adults With DLBCL
Excerpt:
...- Newly diagnosed, untreated, biopsy proven CD20 positive DLBCL (including high grade B-cell lymphoma & T-cell/histiocytic rich large B-cell lymphoma)....
Trial ID:
Source:
Title:
Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
Excerpt:
...- Previously untreated primary mediastinal diffuse large B-cell lymphoma, CD20 positive....
Trial ID:
Source:
Title:
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Excerpt:
...Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse Large B-cell lymphoma confirmed by Laboratory of Pathology, National Cancer Institute (NCI)....
Trial ID:
Source:
Title:
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Excerpt:
...- Histological confirmation of relapsed/refractory CD20 positive diffuse large B-cell lymphoma...
Trial ID:
Source:
Title:
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Excerpt:
...- Pathologically confirmed CD20 positive DLBCL based on 2016 WHO classification who achieved CR after 4 cycles of RCHOP therapy (examined by PET-CT, Deauville score 1-2)...
Trial ID:
Source:
Title:
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
Excerpt:
...Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells....
Trial ID:
Source:
Title:
A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
Excerpt:
...Histologically proven CD20 positive Diffuse Large B-cell Lymphoma according to WHO classification (local pathologist) 2....
Trial ID:
Source:
Title:
An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
Excerpt:
...- Previously untreated CD-20 positive follicular NHL...
Trial ID:
Source:
Title:
Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma
Excerpt:
...- histologically confirmed DLBCL, CD20 positive....
Trial ID:
Source:
Title:
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Excerpt:
...- Patients with CD20-positive diffuse large B-cell lymphoma....
Trial ID:
Source:
Title:
Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma
Excerpt:
...- Histologically confirmed CD20 positive primary breast DLBCL...
Trial ID:
Source:
Title:
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
Excerpt:
...Histologically confirmed CD20-positive DLBCL (The germinal center B-cell like (GCB) / non-GCB subtype was determined by immunohistochemistry in paraffin-embedded tissue using CD10, BCL6 and MUM1 protein markers based on Hans's algorithm); 2....
Trial ID:
Source:
Title:
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Excerpt:
...- Cluster of Differentiation 20 (CD20) positive b lymphocytes....
Trial ID:
Source:
Title:
Lenalidomide and R-CHOP in B-cell Lymphoma
Excerpt:
...- Patients with one of the following B-cell Lymphoma, CD 20 positive:...
Trial ID:
Source:
Title:
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Excerpt:
...- Subjects with CD20 and CD22-positive, follicular or diffuse large B-cell NHL who have...
Trial ID:
Source:
Title:
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Excerpt:
...- CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior therapies; one prior therapy must include anthracyclines and one must include rituximab in combination with chemotherapy...
Trial ID:
Source:
Title:
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Excerpt:
...- Untreated, histological diagnosis of CD20-positive diffuse large B-cell lymphoma...
Trial ID:
Source:
Title:
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
Excerpt:
...Diagnosis of diffuse large B-cell lymphoma, CD20-positive, according to the World Health Organization Classification, stages II-IV or limited stage I disease that is bulky (more than 10 cm) or with International Prognostic Index (IPI) score > 1....
Trial ID:
Source:
Title:
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Excerpt:
...- Histologically confirmed diagnosis of CD20 positive, diffuse large B-cell NHL; de novo or transformed histologies are acceptable...
Trial ID:
Source:
Title:
This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas
Excerpt:
...- Patients must have CD20 positive tumors....
Trial ID:
Source:
Title:
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
Excerpt:
...- CD20-positive disease...
Trial ID:
Source:
Title:
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Excerpt:
...Histologically confirmed CD20 positive DLBCL 2....
Trial ID:
Source:
Title:
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Excerpt:
...- Histologically confirmed CD20-positive, diffuse large B-cell lymphoma...
Trial ID:
Source:
Title:
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
Excerpt:
...Patients with histologically proven diffuse large B-cell (CD20 positive) or transformed follicular non-Hodgkin's lymphomas, that have relapsed after conventional chemotherapy and are...
Trial ID:
Source:
Title:
R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
Excerpt:
...- Histologically confirmed CD20-positive Diffuse Large B-cell Lymphoma (DLBCL), NOS...
Trial ID:
Source:
Title:
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Excerpt:
...- Pathologically confirmed diagnosis of CD20-positive diffuse large B-cell lymphoma...
Trial ID:
Source:
Title:
Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)
Excerpt:
...Histology verified according to the WHO classification and with CD20 positivity by immunhistochemistry or flow cytometry:...
Trial ID:
Source:
Title:
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Excerpt:
...- Diagnosis of CD20-positive diffuse large B-cell lymphoma, including any of the following morphological variants:...
Trial ID:
Source:
Title:
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Excerpt:
...- Tumors must be CD20 positive...
Trial ID:
Source:
Title:
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
Excerpt:
...- Histologically proven CD20 positive diffuse large B-cell non-Hodgkin's lymphoma...
Trial ID:
Source:
Title:
Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma
Excerpt:
...- Histologically confirmed, CD20 positive, diffuse large B-cell lymphoma (DLCL)...
Trial ID:
Source:
Title:
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Excerpt:
...- Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells...
Trial ID:
Source:
Title:
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Excerpt:
...- Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative disorder...
Trial ID:
Source:
Title:
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
Excerpt:
...Histologically confirmed CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) 2....
Trial ID:
Source:
Title:
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
Excerpt:
...- CD20 positive Diffuse large B-Cell lymphoma...
Trial ID:
Source:
Title:
LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Excerpt:
...- Patients with CD20-positive diffuse large B-cell lymphoma...
Trial ID:
Source:
Title:
R Retreatment in 1st Relapsed DLBCL
Excerpt:
...Confirmed CD20 positivity of the lymphoma at time of diagnosis (prior to induction therapy) 4....
Trial ID:
Source:
Title:
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
Excerpt:
...- CD20-positive disease...
Trial ID:
Source:
Title:
'A multi-centre phase II trial of early treatment intensification with R-ICE (rituximab – ifosfamide, carboplatin, etoposide) chemotherapy followed by BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) high dose chemotherapy and autologous stem cell transplantation for patients with poor prognosis diffuse large B-cell lymphoma
Excerpt:
...Diagnosis of CD20-positive diffuse large B-cell lymphoma on biopsy...
Trial ID:
Source:
Title:
A multicenter, double-arm, randomized, prospective II phase controlled clinical trial to evaluate the efficacy and safety of dexitabine combined with R-GDP compared with R-CHOP in patients with mid-term PET-CT positive newly diagnosed diffuse large B-cell lymphoma ((DLBCL)).
Excerpt:
...In patients with diffuse large B-cell lymphoma confirmed by pathology, CD20 was positive; 3. ...
Trial ID:
Source:
Title:
Phase II single centre study assessing the efficacy and safety of I-131 rituximab radioimmunotherapy of relapsed or refractory diffuse large B cell lymphoma.
Excerpt:
...Histologically proven CD 20 positive diffuse large B cell lymphoma, previously treated with a chemotherapy regimen with or without rituximab in patients who have relapsed or are refractory; with a minimum life expectancy of 3 months. ...
Trial ID:
Source:
Title:
Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution
Excerpt:
...All risk groups with good general condition (ECOG 0-2) without majour accompanying diseases after patient's information and written patient's informed consent Patienten im Alter von 61 bis 80 Jahren mit neu diagnostiziertem CD20-positivem aggressivem Lymphom aller Risikogruppen in gutem Allgemeinzustand (ECOG 0-2) ohne wesentliche Begleiterkrankungen nach Aufklärung und schriftlicher Einverständniserklärung...
Trial ID:
Source:
Title:
A randomised controlled, open label, phase II pilot study comparing the toxicity of rituximab plus CHOP chemotherapy with rituximab plus CHOP chemotherapy and bortezomib in adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) being treated in haemato-oncology units within South East Wales
Excerpt:
...Ideally fresh biopsy material should be available at diagnosisd) Bulky stage 1A-1V diseasee) CD20 positive diseasef) Previously untreated diseaseg) No prior diagnosis of indolent lymphoma, including histological transformationh) No clinical evidence of CNS lymphomai) No active malignancy, other than BCC or squamous cell carcinoma of the skin or carcinoma of the cervix in situ, for the past 10 yearsj) Life expectancy > 3 monthsk) Adequate contraceptive precautions for women of childbearing agel) No concurrent uncontrolled medical condition...
Trial ID:
Source:
Title:
Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant study
Excerpt:
...Relapsed or progressive Cluster Designation 20 (CD20) positive diffuse large B-cell lymphoma including induction failures to first-line anthracycline-containing regimens and not usually considered eligible for high dose chemotherapy and stem cell transplantation. ...
Trial ID:
Source:
Title:
The comparative clinical trial with use of two biologic products: MabionCD20 and MabThera in lymphoma patients
Excerpt:
...Patients with histological confirmed CD20 positive diffuse large B cell lymphoma (DLBCL);Patients that had been diagnosed according to the WHO classification;Performance status ≤ 2 on the ECOG/WHO scale, performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated;Patients eligible for rituximab treatment according to MabThera indications;Life expectance at least 6 months;Laboratory values within normal range unless abnormalities are related to lymphoma. ...
Trial ID:
Source:
Title:
A multicenter, prospective, simultaneous controlled and exploratory clinical study on the treatment of new dignosed Diff typinguse large B-cell Lymphoma with RCHOP regimen and X drugs under the guidance of Next Generation Sequencing
Excerpt:
...1) Diffuse large B-cell lymphoma with positive CD20 was confirmed by histopathology. ...
Trial ID:
Source:
Title:
Clinical study of obrutinib, lenalidomide combined with rituximab in the treatment of relapsed/refractory diffuse large B-cell lymphoma in elderly patients based on comprehensive geriatric assessment system
Excerpt:
...Cd20-positive diffuse large B-cell lymphoma independently diagnosed by two pathologists; 2. ...
Trial ID:
Less C2 evidence
Source:
Title:
RITUXIMAB AND NONPEGYLATED LIPOSOMIAL DOXORUBINCIN (R-NPLD) TREATMENT IN PATIENTS 80 YEARS OF AGE OR OLDER AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL): A 2020 UPDATE AND IMPLICATIONS OF CLINICAL AND PATHOLOGICAL FACTORS
Published date:
06/09/2021
Excerpt:
...data of patients 80 years or older with untreated histologically-proven CD20-positive DLBCL...Our results confirm that, in patients 80 years or older with DLBCL, R-NPDL is very effective and safe combination.
Secondary therapy:
non-pegylated liposomal doxorubicin
